Melexis NV
Melexis NV (MLXSF) Financial Performance & Income Statement Overview
Review Melexis NV (MLXSF) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Melexis NV (MLXSF) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Melexis NV MLXSF financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $198.25M | $197.41M | $247.86M | $245.73M |
| Cost of Revenue | $122.57M | $119.85M | $139.62M | $136.96M |
| Gross Profit | $75.68M | $77.56M | $108.24M | $108.77M |
| Gross Profit Ratio | $0.38 | $0.39 | $0.44 | $0.44 |
| R&D Expenses | $28.39M | $30.23M | $26.57M | $26.53M |
| SG&A Expenses | $18.30M | $19.74M | $17.47M | $17.87M |
| Operating Expenses | $46.70M | $49.97M | $44.03M | $44.41M |
| Total Costs & Expenses | -$169.26M | $169.81M | $183.65M | $181.37M |
| Interest Income | $0.00 | $0.00 | $0.00 | $3.37M |
| Interest Expense | $462000.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $12.27M | $11.83M | $11.78M | $12.34M |
| EBITDA | $41.26M | $39.42M | $75.99M | $76.70M |
| EBITDA Ratio | $0.21 | $0.20 | $0.31 | $0.31 |
| Operating Income | $28.98M | $27.59M | $64.21M | $64.36M |
| Operating Income Ratio | $0.15 | $0.14 | $0.26 | $0.26 |
| Other Income/Expenses (Net) | -$462000.00 | -$8.10M | -$1.74M | -$3.37M |
| Income Before Tax | $28.52M | $19.49M | $62.47M | $60.99M |
| Income Before Tax Ratio | $0.14 | $0.10 | $0.25 | $0.25 |
| Income Tax Expense | $3.92M | $1.21M | $11.32M | $11.92M |
| Net Income | $24.60M | $18.28M | $51.15M | $49.07M |
| Net Income Ratio | $0.12 | $0.09 | $0.21 | $0.20 |
| EPS | $0.61 | $0.45 | $1.27 | $1.21 |
| Diluted EPS | $0.61 | $0.45 | $1.27 | $1.21 |
| Weighted Avg Shares Outstanding | $40.32M | $40.44M | $40.28M | $40.40M |
| Weighted Avg Shares Outstanding (Diluted) | $40.32M | $40.44M | $40.28M | $40.40M |
Over the past four quarters, Melexis NV demonstrated steady revenue growth, increasing from $245.73M in Q2 2024 to $198.25M in Q1 2025. Operating income reached $28.98M in Q1 2025, maintaining a consistent 15% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $41.26M, reflecting operational efficiency. Net income rose to $24.60M, with EPS at $0.61. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan